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Background
Sustainable development requires that hidden environ-
mental costs of technologies, that should be paid by
future society, to be taken into account. Scientific meth-
ods and institutions have tended to emphasize the study
of individual natural processes rather than systems, ana-
lysis more than synthesis, and understanding nature
more than predicting its behavior. Science of Medicine
of future is increasingly being called on to produce
knowledge and technology that promote environmen-
tally sustainable, people-oriented development and long-
term management of resources. Unsymmetrical
dimethylhydrazine (UMDH) has extremely toxic (1st
class of danger) and highly carcinogenic properties [1,2].
UMDH was and still is a high quality liquid rocket fuel,
and remains to be indispensable for the latter stages of
ballistic missiles and space. After 1992 about 5000 t of
UMDH in disarmament Ukraine and more than 80,000
t in Russia have accumulated over the years of the Cold
war, creating an extremely serious threat to the environ-
ment and all living being. Therefore, the problem of
complete and irreversible UMDH destruction (utiliza-
tion) can be solved either by complete destruction or to
use UMDH as source for the production of chemical
products, medication (e.g., mildronate and its structure
analogues). The problem of utilization (detoxification)
UMDH was extensively discussed in [1].
The aim
is to develop and implement the own cheap and effec-
tive method of detoxification of unsymmetrical dimethyl
hydrazine for the medical needs.
Technological solution
The first phase includes utilization of unsymmetrical
dimethylhydrazine for chemical synthesis of mildronate
and its structure analogues in specialized chemical
laboratory. In turn, we made a number of demands to
the chemical structures, which can be used as UMDH
acceptors and discovered a new type of chemical inter-
actions of heptyl and its derivatives, suggesting that:
after relevant studies the chemical recycling methods of
heptyl can be greatly expanded, including the medical
aspect. In all cases, the implementation of this idea is
based on the known chemical properties of UMDH and
finding new ways of its transformation. Materials about
the new chemical interactions of heptyl we have not still
published.
Conclusion
Through the use of UMDH in organic synthesis to cre-
ate harmless and promising for practical application
products and thereby solve the problem of its complete
destruction.
Outlook and expert recommendations
It is recommended to create a work group on the basis of
institutions and research centers of the National Academy
of Sciences of Ukraine, authorized to carry out such works
with heptyl. To involve to the project EU research institu-
tions, pharmaceutical industry for scientific and financial
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support. The estimated initial staffing of specialized
laboratory is about 4-5 experts. We suggest tocarry out
the initial stage of study of the pharmacological properties
of the obtained materials at the Institute of Pharmacology
and Toxicology Ministry of Health of Ukraine. The mean
duration of the dismantlement of heptyl to the form of
medical structures is 5-10 years. Further work in this field
depends on the obtained results, as well as a number of
factors that are unpredictable at present.
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